Fuchenchu Wang

Fuchenchu Wang

Auto-generated profile, based on publicly available information

Fuchenchu Wang

MD Anderson, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MLMi Li
Mi Li
ALAmriti R. Lulla
Amriti R. Lulla
YWYan Wang
Yan Wang
STSpyros Tsavaschidis
Spyros Tsavaschidis
FWFuchenchu Wang
Fuchenchu Wang
KKKhandan Keyomarsi
Khandan Keyomarsi
Cyclin E is a regulatory subunit of CDK2 that mediates S phase entry and progression. The cleavage of full-length cyclin E (FL-cycE) to low–molecular weight isoforms (LMW-E) dramatically alters substrate specificity, promoting G1–S cell cycle transition and accelerating mitotic exit. Approximately 70% of triple-negative breast cancers (TNBC) express LMW-E, which correlates with poor prognosis. PKMYT1 also plays an important role in mitosis by inhibiting CDK1 to block premature mitotic entry, suggesting it could be a therapeutic target in TNBC expressing LMW-E. In this study, analysis of tumor samples of patients with TNBC revealed that coexpression of LMW-E and PKMYT1-catalyzed CDK1 phosphorylation predicted poor response to neoadjuvant chemotherapy. Compared with FL-cycE, LMW-E specifically upregulates PKMYT1 expression and protein stability, thereby increasing CDK1 phosphorylation. Inhibiting PKMYT1 with the selective inhibitor RP-6306 (lunresertib) elicited LMW-E–dependent antitumor effects, accelerating premature mitotic entry, inhibiting replication fork restart, and enhancing DNA damage, chromosomal breakage, apoptosis, and replication stress. Importantly, TNBC cell line xenografts expressing LMW-E showed greater sensitivity to RP-6306 than tumors with empty vector or FL-cycE. Furthermore, RP-6306 exerted tumor suppressive effects in LMW-E transgenic murine mammary tumors and patient-derived xenografts of LMW-E–high TNBC but not in the LMW-E null models examined in parallel. Lastly, transcriptomic and immune profiling demonstrated that RP-6306 treatment induced interferon responses and T-cell infiltration in the LMW-E–high tumor microenvironment, enhancing the antitumor immune response. These findings highlight the LMW-E/PKMYT1/CDK1 regulatory axis as a promising therapeutic target in TNBC, providing the rationale for further clinical development of PKMYT1 inhibitors in this aggressive breast cancer subtype. Significance: PKMYT1 upregulation and CDK1 phosphorylation in triple-negative breast cancer expressing low–molecular weight cyclin E leads to suboptimal responses to chemotherapy but sensitizes tumors to PKMYT1 inhibitors, proposing a personalized treatment strategy.

22 March 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
AFAlvin Jay Freeman
Alvin Jay Freeman
KNKenneth Ng
Kenneth Ng
FWFuchenchu Wang
Fuchenchu Wang
MAMaisam A. Abu-El-Haija
Maisam A. Abu-El-Haija
ACAnkur Chugh
Ankur Chugh
AUAliye Uc
Aliye Uc
INTRODUCTION: Among children who suffer from acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP), acute pancreatitis (AP) episodes are painful, often require hospitalization, and contribute to disease complications and progression. Despite this recognition, there are currently no interventions to prevent AP episodes. In this retrospective cohort study, we assessed the impact of pancreatic enzyme therapy (PERT) use on clinical outcomes among children with pancreatic-sufficient ARP or CP. METHODS: Children with pancreatic-sufficient ARP or CP in the INSPPIRE-2 cohort were included. Clinical outcomes were compared for those receiving vs not receiving PERT, as well as frequency of AP before and after PERT. Logistic regression was used to study the association between development of AP episodes after starting PERT and response predictors. RESULTS: Among 356 pancreatic-sufficient participants, 270 (76%) had ARP, and 60 (17%) received PERT. Among those on PERT, 42% did not have a subsequent AP episode, during a mean 2.1 years of follow-up. Children with a SPINK1 mutation (P = 0.005) and those with ARP (compared with CP, P = 0.008) were less likely to have an AP episode after starting PERT. After initiation of PERT, the mean AP annual incidence rate decreased from 3.14 down to 0.71 (P < 0.001). DISCUSSION: In a retrospective analysis, use of PERT was associated with a reduction in the incidence rate of AP among children with pancreatic-sufficient ARP or CP. These results support the need for a clinical trial to evaluate the efficacy of PERT to improve clinical outcomes among children with ARP or CP.

15 March 2024 in Science Advances
Verified
Journal Article
Open access
IHI-Lin Ho
I-Lin Ho
CLChieh-Yuan Li
Chieh-Yuan Li
FWFuchenchu Wang
Fuchenchu Wang
LZLi Zhao
Li Zhao
JLJingjing Liu
Jingjing Liu
AVAndrea Viale
Andrea Viale
Tumors represent ecosystems where subclones compete during tumor growth. While extensively investigated, a comprehensive picture of the interplay of clonal lineages during dissemination is still lacking. Using patient-derived pancreatic cancer cells, we created orthotopically implanted clonal replica tumors to trace clonal dynamics of unperturbed tumor expansion and dissemination. This model revealed the multifaceted nature of tumor growth, with rapid changes in clonal fitness leading to continuous reshuffling of tumor architecture and alternating clonal dominance as a distinct feature of cancer growth. Regarding dissemination, a large fraction of tumor lineages could be found at secondary sites each having distinctive organ growth patterns as well as numerous undescribed behaviors such as abortive colonization. Paired analysis of primary and secondary sites revealed fitness as major contributor to dissemination. From the analysis of pro- and nonmetastatic isogenic subclones, we identified a transcriptomic signature able to identify metastatic cells in human tumors and predict patients’ survival.

31 August 2023 in Pancreatology
Verified
Journal Article
Closed access
MAMaisam A. Abu-El-Haija
Maisam A. Abu-El-Haija
LHLindsey Hornung
Lindsey Hornung
KEKate Ellery
Kate Ellery
DFDouglas S. Fishman
Douglas S. Fishman
TGTanja Y. Gonska
Tanja Y. Gonska
HKHeidi J. Kalkwarf
Heidi J. Kalkwarf

2 February 2026 in Pancreatology
Verified
Journal Article
Closed access
EDElissa M. Downs
Elissa M. Downs
EPEmily R. Perito
Emily R. Perito
FWFuchenchu Wang
Fuchenchu Wang
GCGretchen A. Cress
Gretchen A. Cress
MAMaisam Abu-El-Haija
Maisam Abu-El-Haija
AUAliye Uc
Aliye Uc

18 November 2024
Verified
Other
Open access
MLMi Li
Mi Li
ALAmriti R. Lulla
Amriti R. Lulla
YWYan Wang
Yan Wang
STSpyros Tsavaschidis
Spyros Tsavaschidis
FWFuchenchu Wang
Fuchenchu Wang
KKKhandan Keyomarsi
Khandan Keyomarsi
This file contains all the information pertaining to supplementary methods that were referred to in the supplementary data.